Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival is a research paper published in Frontiers in Oncology (2023). On theSindex it has a DataRank of 0.360. It has been cited 10 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.360
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: P01 CA155258
NCI NIH HHS
Grant: P50 CA100707
BLRD VA
Grant: I01 BX001584
FWCI
1.83
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals